The secretary general for health and consumers and president of Spanish Agency of Medicines and Health Products, Pilar Farjas, inaugurated this conference which has aimed to present the main strategies and actions that are contemplated in Plan National Strategic and Action to reduce the risk of selection and spread of antimicrobial resistance, as well as presenting the main activities in this field are being carried out by the Government. For more relevant information, check out my link http://www.reviewlity.com/
The bacteria developing resistance to antimicrobial drugs is now regarded as one of the major public health problems. According to the European Centre for Disease Prevention and Control, ECDC and the European Medicines Agency, EMA, around 25,000 patients die each year in the European Union due to an infection caused by multidrug-resistant bacteria, with added costs of approximately 1,500 million euros for extra hospital care, medical care and lost productivity. Inappropriate and indiscriminate use of antibiotics is one of the main factors contributing to this phenomenon.
The Council of the European Union, the European Parliament, the European Commission, its Agencies (EMA, ECDC, EFSA) and the network of agencies have identified the need to establish a common strategy Europe to assess and address this problem of development of antimicrobial resistance.
In the European Action Plan on Antimicrobial Resistance includes 12 stocks that are identified as key in the fight against the resistance in the Member States and should be developed for each of these. See Wikipedia link also http://en.wikipedia.org/wiki/Antibiotics
To comply with this mandate, from the Competent Authority was the creation of a multidisciplinary working group with the aim of developing a strategy and action plan for reducing the risk of selection and spread of antibiotic resistance. This group includes members from the Ministries of Health, Social Services and Equality, of Agriculture, Food and the Environment and the Economy and Competitiveness as well as universities, the Spanish Committee of Susceptibility (COESANT), Scientific Societies and Organizations Medical College, Veterinary and pharmaceutical to ensure a comprehensive approach to the problem.